Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupMEDGF +90.68%71 Debt-to-EBITDA is 1.67 as of Dec. 2025, which is 9% above its 10-year median of 1.53. GuruFocus rates MEDGF with a GF Score™ of 71/100 and a GF Value™ of $90.63 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Medacta Group ranks better than 53.75% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Medacta Group's Debt-to-EBITDA or its related term are showing as below:
MEDGF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.6 Med: 1.53 Max: 3
Current: 1.32
During the past 11 years, the highest Debt-to-EBITDA Ratio of Medacta Group was 3.00. The lowest was 0.60. And the median was 1.53.
MEDGF's Debt-to-EBITDA is ranked better than 53.75% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs MEDGF: 1.32
Medacta Group (OTCPK:MEDGF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medacta Group Debt-to-EBITDA Related Terms
Medacta Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Medacta Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medacta Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medacta Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Medacta Group (MEDGF) has a Debt-to-EBITDA of 1.67 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medacta Group. This is near median its historical median of 1.53. Over the past decade, Medacta Group's Debt-to-EBITDA has ranged from 0.60 to 3.00. According to the industry distribution chart, Medacta Group ranks #216 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 46.3%.
Is Medacta Group's Debt-to-EBITDA too high?
Medacta Group's current Debt-to-EBITDA of 1.67 is near median its 10-year median of 1.53. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 3.00. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Medacta Group's value of 1.67 is 4.4% above this industry median. Based on the distribution chart, Medacta Group ranks #216 out of 467 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medacta Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #216 out of 467 companies for Debt-to-EBITDA. This puts Medacta Group in the upper half of its industry. The industry median Debt-to-EBITDA is 1.60. Medacta Group's value of 1.67 is 4.4% above this benchmark. Historically, Medacta Group's own Debt-to-EBITDA has ranged from 0.60 to 3.00 over the past decade. While the company's 10-year median is 1.53 vs. the industry median of 1.60, Medacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current Debt-to-EBITDA of 1.67 is 4.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medacta Group. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current Debt-to-EBITDA is 1.67, which is near median its own 10-year median of 1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (MEDGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $90.63, compared to a current price of $160.00 — trading 76.5% above its estimated fair value. The current Debt-to-EBITDA is 1.67, which is near median its 10-year median of 1.53 and 4.4% above the Medical Devices & Instruments industry median of 1.60. Medacta Group's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Medacta Group (MEDGF), the current Debt-to-EBITDA is 1.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (MEDGF) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be overvalued.
The current stock price of $160.00 is trading 76.5% above its estimated GF Value™ of $90.63.
GuruFocus considers Medacta Group to be Significantly Overvalued.
Key valuation signals for MEDGF:
Debt-to-EBITDA: 1.67 (near median its 10-year median of 1.53)
GF Value™: $90.63 vs. price of $160.00 (76.5% above fair value)
Industry Position: 4.4% above the Medical Devices & Instruments median (#216 of 467)
No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
71GF Score
Get the complete analysis for MEDGF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDGF has been successfully added to your 
